Stockscreener 앱 받기
0.4126
0.70%
-0.0029
시간 외 거래:
.40
-0.0126
-3.05%
전일 마감가:
$0.4155
열려 있는:
$0.415
하루 거래량:
1.29M
Relative Volume:
0.80
시가총액:
$60.73M
수익:
-
순이익/손실:
$-54.17M
주가수익비율:
-1.1154
EPS:
-0.3699
순현금흐름:
$-39.34M
1주 성능:
-85.05%
1개월 성능:
-85.57%
6개월 성능:
-74.37%
1년 성능:
-78.40%
1일 변동 폭
$0.3918
$0.4213
1주일 범위
$0.3918
$0.5592
52주 변동 폭
$0.3918
$3.5299
Immutep Limited Adr Stock (IMMP) Company Profile
Compare IMMP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMP
Immutep Limited Adr
|
0.4126 | 61.16M | 0 | -54.17M | -39.34M | -0.3699 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immutep Limited Adr Stock (IMMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 다운그레이드 | Citizens | Mkt Outperform → Mkt Perform |
| 2026-03-13 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2026-03-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2026-02-17 | 개시 | Citizens | Mkt Outperform |
| 2024-05-17 | 개시 | CapitalOne | Overweight |
| 2023-08-03 | 개시 | Robert W. Baird | Outperform |
| 2021-08-03 | 개시 | Ladenburg Thalmann | Buy |
| 2021-07-16 | 재개 | Maxim Group | Buy |
| 2018-09-28 | 개시 | B. Riley FBR | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
모두보기
Immutep Limited Adr 주식(IMMP)의 최신 뉴스
IMMP Investor News: If You Have Suffered Losses in Immutep - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep LimitedIMMP - PR Newswire
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action InvestigationIMMP - PR Newswire
On Wednesday, there are stocks with unusual volume. Let's take a look. - ChartMill
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep LimitedIMMP - FinancialContent
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP - Business Wire
On Tuesday, there are stocks with unusual volume. Let's take a look. - ChartMill
IMM:ASX AnnouncementChange in substantial holding17 Mar 2026 - Market Index
Horizon Technology Finance Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
[6-K] IMMUTEP Ltd Current Report (Foreign Issuer) | IMMP SEC FilingForm 6-K - Stock Titan
Crude Oil Gains Over 1%; VEON Shares Spike Higher - Sahm
Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early - Sahm
This Karman Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Sahm
Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4 - Sahm
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% By Investing.com - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - Investing.com
This EverCommerce analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
This EverCommerce Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
US Market Preview | PCE in Line; ISPC Soars 86.7%; Oil Spikes Amid Iran’s Leader Talk; AI Wealth Boom Adds 45 Billionaires - Sahm
IMMP Stock Price, Quote & Chart | IMMUTEP LTD-SP ADR (NASDAQ:IMMP) - ChartMill
Orchestra BioMed (NASDAQ:OBIO) versus Prima BioMed (NASDAQ:IMMP) Critical Analysis - Defense World
Immutep reports positive phase I data for first-in-class autoimmune antibody IMP761 - MSN
Why Immutep Limited (Common Stock) (YP1A) stock is trending on social mediaHealthcare Stock Analysis & Investment Portfolio Recommendations - Bollywood Helpline
Immutep (IMMP) reports positive IMP761 Phase I study update - Stock Titan
Why Wall Street Is Watching Immutep's Experimental Autoimmune Treatment Closely - Sahm
Will Immutep Limited Depositary Receipt stock see insider buying2025 Bull vs Bear & Accurate Intraday Trading Signals - Улправда
Why Immutep Limited (YP1B) stock is a strong analyst pickWeekly Risk Summary & AI Powered Trade Plan Recommendations - Улправда
Immutep Limited (IMMP): Firm Reports Positive Data from Trials - Finviz
Ready to Jump After Recent Trade: Beta Bionics Inc (BBNX) - setenews.com
An analyst sees good growth prospects for Immutep Limited ADR (IMMP) - setenews.com
Immutep Limited Announces 2025 AGM with Key Resolutions - MSN
IMMP 20-F highlights: pipeline progress, IFRS results, Nasdaq ADSs - Stock Titan
Immutep reports Phase II neoadjuvant efti success in sarcoma via 6-K - Stock Titan
Immutep Completes FDA Project Optimus, Advances Cancer Immunotherapy - MSN
Immutep files 6-K with exhibit on FDA Project Optimus completion - Stock Titan
Immutep Announces Successful Completion of FDA Project Optimus Requirements - The Manila Times
Is Immutep Limited Depositary Receipt stock ready for a breakoutPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa - Yahoo Finance
Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data - Finviz
Immutep stock soars on promising trial results By Investing.com - Investing.com Australia
Immutep Limited (NASDAQ: IMMP)Share Price - intelligentinvestor.com.au
JK Paper slides over 7% after Q1 net profit declines 55% YoY to ₹140.79 crore - Upstox
Which stocks are moving before the opening bell on Thursday? - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
OversoldStock ScreenerCharts - Finviz
DowngradesStock ScreenerSnapshot - Finviz
New LowStock ScreenerSnapshot - Finviz
Top LosersStock ScreenerSnapshot - Finviz
Immutep Announces Successful Meeting with the FDA on - GlobeNewswire
Immutep Limited Adr (IMMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):